Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press95710.17650/1726-9776-2020-16-1-106-113REVIEWОБЗОРMolecular subtypes of bladder cancer and first success in personalized treatmentМолекулярные подтипы рака мочевого пузыря и первые успехи в персонализированном лечении.https://orcid.org/0000-0002-7877-8344OsetnikV. K.ОсетникВ. К.Russian Federation
154, Fontanka River Embankment, Saint Petersburg 190103
Клиника высоких медицинских технологий им. Н.И. Пирогова
190103 Санкт-Петербург,набережная реки Фонтанки, 154
MamizhevE. M.МамижевЭ. М.Russian Federation
154, Fontanka River Embankment, Saint Petersburg 190103
Эльдар Мухамедович Мамижев,врач онколог, онкологического отделения с хирургическим блоком
190103 Санкт-Петербург,набережная реки Фонтанки, 154
68 Leningradskaya St., Pesochniji, Saint Petersburg 197758
Saint Petersburg State University HospitalКлиника высоких технологий им. Н. И. Пирогова Санкт-Петербургского государственного университетаSaint Petersburg State University HospitalНИИ онкологии им.Н.Н.ПетроваN.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России300320201611061131906201909082019https://oncourology.abvpress.ru/oncur/article/view/957
In the literature review we described studies, the main purpose of which was to distribute bladder tumors by molecular subtypes. A similar classification has long been actively used in the treatment of breast cancer. The pioneering work in the molecular subtypes of bladder cancer includes the work by Lund group, the TCGA (The Cancer Genome Atlas) project, the MD Anderson study. We have also included data on attempts to apply molecular taxonomy of bladder cancer in treatment.
В представленном обзоре литературы рассмотрены исследования, основной целью которых было распределить опухоли мочевого пузыря по молекулярным подтипам. Схожая классификация уже давно активно используется при лечении рака молочной железы. К основополагающим работам в области молекулярных подтипов рака мочевого пузыря относятся исследования группы Лунда, проект TCGA, ислледования MD Anderson. Также, мы включили данные о попытках применения молекулярной таксономии рака мочевого пузыря в лечении.
bladder cancermolecular subtypebladder cancer treatmentimmunohistochemistryрак мочевого пузырямолекулярные подтипылечение рака мочевого пузыряимуногистохимиянетKirkali, Ziya, et al. "Bladder cancer: epidemiology, staging and grading, and diagnosis." Urology 66.6 (2005): 4-34.Kirkali Z., Chan T., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6):4–34. DOI: 10.1016/j.urology.2005.07.062.Seigel, R., D. Naishadham, and A. Jemal. "Cancer statistics, 2014." Ca Cancer J Clin 64.1 (2014): 9-29.Seigel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 64(1):9–29. DOI: 10.3322/caac.21551.Simonis, K., Shariat, S. F., & Rink, M. (2014). Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Current opinion in urology, 24(5), 492-499.Simonis K., Shariat S.F., Rink M. et al. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Curr Opin Urol 2014;24(5):492–9. DOI: 10.1097/MOU.0000000000000079.Botteman, Marc F., et al. "The health economics of bladder cancer." Pharmacoeconomics 21.18 (2003): 1315-1330.Botteman M.F. The health economics of bladder cancer. Pharmacoeconomics 2003;21(18):1315–30. DOI: 10.1007/BF03262330.Shah, Jay B., David J. McConkey, and Colin PN Dinney. "New strategies in muscle-invasive bladder cancer: on the road to personalized medicine." Clinical Cancer Research 17.9 (2011): 2608-2612.Shah J.B., McConkey D.J., Dinney C.P. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 2011;17(9): 2608–12. DOI: 10.1158/1078-0432.CCR-10-2770.Rouzier, Roman, et al. "Breast cancer molecular subtypes respond differently to preoperative chemotherapy." Clinical cancer research11.16 (2005): 5678-5685.Rouzier R., Perou C.M., Symmans W.F. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678–85. DOI: 10.1158/1078-0432.CCR-04-2421.Lindgren, David, et al. "Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome." Cancer research 70.9 (2010): 3463-3472.Lindgren D., Frigyesi A., Gudjonsson S. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70(9):3463–72. DOI: 10.1158/0008-5472.CAN-09-4213.Sjödahl, Gottfrid, et al. "A molecular taxonomy for urothelial carcinoma." Clinical cancer research 18.12 (2012): 3377-3386.Sjödahl G., Lauss M., Lövgren K. et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012;18(12): 3377–86. DOI: 10.1158/1078-0432.CCR-12-0077-T.Lindgren, David, et al. "Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma." PloS one 7.6 (2012): e38863.Lindgren D., Sjödahl G., Lauss M. et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PloS One 2012;7(6):e38863. DOI: 10.1371/journal.pone.0038863.Sjödahl, Gottfrid, et al. "Toward a molecular pathologic classification of urothelial carcinoma." The American journal of pathology 183.3 (2013): 681-691.Sjödahl G., Lövgren K., Lauss M. et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 2013;183(3):681–91. DOI: 10.1016/j.ajpath.2013.05.013.Patschan, Oliver, et al. "A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma." European urology 68.5 (2015): 824-832.Patschan O., Sjödahl G., Chebil G. et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol 2015;68(5):824–32. DOI: 10.1016/j.eururo.2015.02.021.Cancer Genome Atlas Research Network. "Comprehensive molecular characterization of urothelial bladder carcinoma." Nature 507.7492 (2014): 315.Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315–22. DOI: 10.1038/nature12965.Volkmer, Jens-Peter, et al. "Three differentiation states risk-stratify bladder cancer into distinct subtypes." Proceedings of the National Academy of Sciences 109.6 (2012): 2078-2083.Volkmer J.P., Sahoo D., Chin R.K. et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA 2012;109(6):2078–83. DOI: 10.1073/pnas.1120605109.Ho, Philip Levy, Antonina Kurtova, and Keith Syson Chan. "Normal and neoplastic urothelial stem cells: getting to the root of the problem." Nature reviews Urology 9.10 (2012): 583.Ho P.L., Kurtova A., Chan K.S. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 2012;9(10):583–94. DOI: 10.1038/nrurol.2012.142.Hoadley, Katherine A., et al. "Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin." Cell 158.4 (2014): 929-944.Hoadley K.A., Yau C., Wolf D.M. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158(4):929–44. DOI: 10.1016/j.cell.2014.06.049.Perou, Charles M., et al. "Molecular portraits of human breast tumours." Nature 406.6797 (2000): 747.Perou C.M., Sørlie T., Eisen M.B. et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747–52. DOI: 10.1038/35021093.Sørlie, Therese, et al. "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications." Proceedings of the National Academy of Sciences 98.19 (2001): 10869-10874.Sørlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869–74. DOI: 10.1073/pnas.191367098.Choi, Woonyoung, et al. "Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy." Cancer cell 25.2 (2014): 152-165.Choi W., Porten S., Kim S. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25(2):152–65. DOI: 10.1016/j.ccr.2014.01.009.Choi, Woonyoung, et al. "Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer." Nature Reviews Urology 11.7 (2014): 400.Choi W., Czerniak B., Ochoa A. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 2014;11(7):400–10. DOI: 10.1038/nrurol.2014.129.McConkey, David J., Woonyoung Choi, and Colin PN Dinney. "New insights into subtypes of invasive bladder cancer: considerations of the clinician." European urology 66.4 (2014): 609-610.McConkey D.J., Choi W., Dinney C.P. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66(4):609–10. DOI: 10.1016/j.eururo.2014.05.006.Damrauer, Jeffrey S., et al. "Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology." Proceedings of the National Academy of Sciences 111.8 (2014): 3110-3115.Damrauer J.S., Hoadley K.A., Chism D.D. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 2014;111(8):3110–15. DOI: 10.1073/pnas.1318376111.Lauss, Martin, et al. "DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status." Epigenetics7.8 (2012): 858-867.Lauss M., Aine M., Sjödahl G. et al. DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics 2012;7(8):858–67. DOI: 10.4161/epi.20837.Aine, Mattias, et al. "Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma." Genome medicine 7.1 (2015): 23.Aine M., Sjödahl G., Eriksson P. et al. Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma. Genome Med 2015;7(1):23. DOI: 10.1186/s13073-015-0144-4.Lerner, Seth P., et al. "Bladder cancer molecular taxonomy: summary from a consensus meeting." Bladder Cancer 2.1 (2016): 37-47.Lerner S.P., McConkey D.J., Hoadley K.A. et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2016;2(1):37–47. DOI: 10.3233/BLC-150037.Seiler, Roland, et al. "Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy." European urology 72.4 (2017): 544-554.Seiler R., Ashab H.A.D., Erho N. et al. Impact of molecular subtypes in muscleinvasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 2017;72(4):544– 54. DOI: 10.1016/j.eururo.2017.03.030.Liu, David, et al. "Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer." Nature communications 8.1 (2017): 2193.Liu D., Abbosh P., Keliher D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun 2017;8(1):2193. DOI: 10.1038/s41467-017-02320-7.Robertson, A. Gordon, et al. "Comprehensive molecular characterization of muscle-invasive bladder cancer." Cell 171.3 (2017): 540-556.Robertson A.G., Kim J., Al-Ahmadie H. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017;171(3):540–56. DOI: 10.1016/j.cell.2017.09.007.